Capromorelin for Appetite Support: Cause, Species, and Monitoring

Capromorelin is a ghrelin-receptor agonist used in species- and product-specific veterinary appetite settings; it does not replace evaluation of why intake fell.

The prescription oral medicine stimulates appetite-related signaling. Veterinary products and labels differ by species and market, so the exact formulation and current client information matter.

It may be considered after nausea, pain, dental or swallowing problems, constipation, food aversion, metabolic disease, and obstruction have been reviewed and when the patient can safely eat.

A symptom-control plan may protect comfort, hydration, nutrition, sleep, mobility, and treatment continuity while the team also investigates the cause. Success means a defined improvement in the patient’s function or comfort, not simply suppressing a warning sign.

The prescriber considers the suspected cause, severity, organ function, cancer treatment, comorbidities, all medicines and supplements, previous reactions, and what can safely be managed at home. Families need written start, stop, missed-dose, and escalation instructions.

Veterinary pharmacology and oncology guidance recognize capromorelin as an appetite option. A patient eating more is a supportive outcome, not evidence of cancer control, complete nutrition, or correction of the underlying cause.

Gastrointestinal effects, drooling, thirst or metabolic effects, lethargy, and patient-specific organ or endocrine concerns require monitoring. Continued weight or muscle loss despite apparent appetite needs reassessment.

Do not use another pet’s or a person’s medicine, combine products, repeat a vomited dose, or alter a prescription without instructions. Severe weakness, collapse, breathing difficulty, uncontrolled pain, repeated vomiting, inability to urinate, major bleeding, or rapid deterioration warrants urgent assessment.